Introduction: There is increasing interest in the potential for psychedelic drugs such as
psilocybin, LSD and ketamine to treat several mental health disorders, with a growing …

Placebo and Nocebo Effects Placebo and nocebo effects (effects of patients' positive and
negative expectations) are powerful and pervasive in clinical practice. Neurobiologic …

Abstract Treatment outcomes for major depressive disorder (MDD) need to be improved.
Presently, no clinically relevant tools have been established for stratifying subgroups or …

Patient-reported outcome measures (PROMs) are self-rated scales and indices developed
to improve the detection of the patients' subjective experience. Given that a considerable …

Importance Approximately one-third of patients with major depressive disorder (MDD) do not
respond to available antidepressants. Objective To assess the efficacy, safety, and dose …

Background Patients suffering from depression experience significant mood, anxiety, and
cognitive symptoms. Currently, most antidepressants work by altering neurotransmitter …

Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing
substantial distress for both people with dementia and their caregivers, and contributing to …

Objective: Altered glutamatergic neurotransmission is implicated in the pathogenesis of
major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA …

Despite considerable progress in pharmacotherapy over the past seven decades, many
mental disorders remain insufficiently treated. This situation is in part due to the limited …

Autism spectrum disorder (ASD) is characterized by core social deficits. Prognosis is poor, in
part, because existing medications target only associated ASD features. Emerging evidence …